Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver disease

INTRODUCTION: Non-alcoholic fatty liver disease (NAFLD) pathogenesis involves abnormal metabolism of cholesterol and hepatic accumulation of toxic free-cholesterol. Elobixibat (EXB) inhibits the ileal bile acid (BA) transporter. EXB and cholestyramine (CTM) facilitate the removal of free cholesterol...

Descripción completa

Detalles Bibliográficos
Autores principales: Kessoku, Takaomi, Kobayashi, Takashi, Ozaki, Anna, Iwaki, Michihiro, Honda, Yasushi, Ogawa, Yuji, Imajo, Kento, Saigusa, Yusuke, Yamamoto, Koji, Yamanaka, Takeharu, Usuda, Haruki, Wada, Koichiro, Yoneda, Masato, Saito, Satoru, Nakajima, Atsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Gastroenterology and Hepatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7482497/
https://www.ncbi.nlm.nih.gov/pubmed/32907904
http://dx.doi.org/10.1136/bmjopen-2020-037961

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7482497/
https://www.ncbi.nlm.nih.gov/pubmed/32907904
http://dx.doi.org/10.1136/bmjopen-2020-037961

Ejemplares similares